Marqibo® (vincristine sulfate liposomes injection)

DRUG2 trials

Sponsors

Spectrum Pharmaceuticals, Inc

Conditions

Acute Lymphoblastic Leukemia (ALL)Metastatic Malignant Uveal Melanoma

Phase 2

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

CompletedNCT00495079

Spectrum Pharmaceuticals, IncAcute Lymphoblastic Leukemia (ALL)

Start: 2007-05-31End: 2010-08-08Updated: 2021-03-05

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

CompletedNCT00506142

Spectrum Pharmaceuticals, IncMetastatic Malignant Uveal Melanoma

Start: 2007-11-30End: 2014-12-31Updated: 2019-12-11

Related Papers

High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.

2018-09-2120 citations